Detalles de la búsqueda
1.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet;
395(10240): 1845-1854, 2020 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32450106
2.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet;
396(10249): 479-488, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702299
3.
Coronavirus disease 2019 vaccines: landscape of global studies and potential risks.
Chin Med J (Engl);
134(17): 2037-2044, 2021 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34343152
4.
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
Signal Transduct Target Ther;
6(1): 271, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34267185
Resultados
1 -
4
de 4
1
Próxima >
>>